Experimental and clinical evidence for brimonidine as an optic nerve and retinal neuroprotective agent:An evidence-based review

Archives of Ophthalmology

Volumn 127, Issue 4, 2009, Pages 402-406

  Saylor, Meredith ^a   McLoon, Linda K ^a   Harrison, Andrew R ^a   Lee, Michael S ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR; BRIMONIDINE; PLACEBO;

APOPTOSIS; ARTICLE; CLINICAL TRIAL; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG PENETRATION; DRUG TARGETING; DRUG TOLERABILITY; GLAUCOMA; HUMAN; INTRAOCULAR HYPERTENSION; ISCHEMIC OPTIC NEUROPATHY; NEUROPROTECTION; NONHUMAN; OPTIC NERVE; OPTIC NERVE INJURY; PRIORITY JOURNAL; RETINA DEGENERATION; RETINA DYSTROPHY; RETINA GANGLION CELL; RETINA INJURY; UNSPECIFIED SIDE EFFECT; VISUAL ACUITY; VISUAL FIELD;

ADRENERGIC ALPHA-AGONISTS; ANIMALS; HUMANS; NEUROPROTECTIVE AGENTS; OPTIC NEUROPATHY, ISCHEMIC; QUINOXALINES; RETINA; RETINAL DISEASES; VITREOUS BODY;

EID: 65249098513     PISSN: 00039950     EISSN: 15383601     Source Type: Journal    
DOI: 10.1001/archophthalmol.2009.9     Document Type: Article

References (48)

1. Aktaş Z, Gürelik G, Akÿrek N, Onol M, Hasanreisoǧlu B. Neuroprotective effect of topically applied brimonidine tartrate 0.2% in endothelin- I- induced optic nerve ischaemia model. Clin Experiment Ophthalmol. 2007;35(6):527-534.
2. Kent AR, Nussdorf JD, David R, Tyson F, Small D, Fellows D. Vitreous concentration of topically applied brimonidine tartrate 0.2%. Ophthalmology. 2001; 108(4):784-787.
3. Wheeler LA, Gil DW, WoldeMussie E. Role of alpha-2 adrenergic receptors in neuroprotection and glaucoma. Surv Ophthalmol. 2001;45(suppl 3):S290-S296.
4. Wheeler L, WoldeMussie E, Lai R. Role of alpha-2 agonists in neuroprotection. SurvOphthalmol. 2003;48(suppl 1):S47-S51.
5. Hernandez M, Urcola JH, Vecino E. Retinal ganglion cell neuroprotection in a rat model of glaucoma following brimonidine, latanoprost or combined treatments. Exp Eye Res. 2008;86(5):798-806.
6. Cantor LB. The evolving pharmacotherapeutic profile of brimonidine, an alpha 2-adrenergic agonist, afterfouryears of continuous use. ExpertOpin Pharmacother. 2000;1(4):815-834.
7. Lachkar Y, Migdal C, Dhanjil S. Effect of brimonidine tartrate on ocular hemodynamic measurements. Arch Ophthalmol. 1998;116(12):1591-1594.
8. Carlsson AM, Chauhan BC, Lee AA, LeBlanc RP. The effect of brimonidine tartrate on retinal blood flow in patients with ocular hypertension [corrected and republished in Am J Ophthalmol. 2000;129(3):297-301]. Am J Ophthalmol. 2000; 129(3):297-301.
9. Sherwood MB, Craven ER, Chou C, et al. Twice-daily 0.2% brimonidine-0.5% timolol fixed-combination therapy vs monotherapy with timolol or brimonidine in patients with glaucoma or ocular hypertension. Arch Ophthalmol. 2006; 124(9):1230-1238.
10. Acheampong AA, Shackleton M, John B, Burke J, Wheeler L, Tang-Liu D. Distribution of brimonidine into anterior and posterior tissues of monkey, rabbit, and rat eyes. Drug Metab Dispos. 2002;30(4):421-429.
11. Bittiger H, Heid J, Wigger N. Are only alpha 2-adrenergic receptors present in bovine retina? Nature. 1980;287(5783):645-647.
12. Osborne NN. Binding of (-)[3H]noradrenaline to bovine membrane of the retina: evidence for the existence of alpha 2-receptors. Vision Res. 1982;22(11):1401-1407.
13. Zarbin MA, Wamsley JK, Palacios JM, Kuhar MJ. Autoradiographic localization of high affinity GABA, benzodiazepine, dopaminergic, adrenergic and muscarinic cholinergic receptors in the rat, monkey and human retina. Brain Res. 1986; 374(1):75-92.
14. Elena PP, Kosina-Boix M, Denis P, Moulin G, Lapalus P. Alpha2-adrenergic receptors in rat and rabbit eye: a tritium-sensitive film autoradiography. Ophthal- micRes. 1989;21(4):309-314.
15. Matsuo T, Cynader MS. Localization of alpha-2 adrenergic receptors in the human eye. Ophthalmic Res. 1992;24(4):213-219.
16. Huang Y, Gil DW, Vanscheeuwijck P, Stamer WD, Regan JW. Localization of alpha 2-adrenergic receptor subtypes in the anterior segment of the human eye with selective antibodies. Invest Ophthalmol Vis Sci. 1995;36(13):2729-2739.
17. Woldemussie E, Wijono M, Pow D. Localization of alpha 2 receptors in ocular tissues. Vis Neurosci. 2007;24(5):745-756.
18. 2-adrenergic receptor subtypes in human ocular tissue homogenates. Invest Ophthalmol Vis Sci. 1999;40(10):2299-2306.
19. Peng M, Li Y, Luo Z, Liu C, Laties AM, Wen R. Alpha2-adrenergic agonists selectively activate extracellularsignal-regulated kinases in Müller cells in vivo. Invest Ophthalmol Vis Sci. 1998;39(9):1721-1726.
20. 2- adrenoceptor stimulation in rabbit retina. Brain Res. 1991;553(1):84-88.
21. Hadjiconstantinou M, Cohen J, Rubenstein JS, Neff NH. An endogenous ligand modulates dopamine-containing neurons of retina via alpha-2 adrenoceptors. J Pharmacol Exp Ther. 1984;229(2):381-385.
22. Yoles E, Wheeler LA, Schwartz M. Alpha2-adrenoreceptor agonists are neuro- protective in a rat model of optic nerve degeneration [published correction appears in Invest Ophthalmol Vis Sci. 1999;40(11):2470]. Invest Ophthalmol Vis Sci. 1999;40(1):65-73.
23. Wen R, Cheng T, Li Y, Cao W, Steinberg RH. Alpha 2-adrenergic agonists induce basic fibroblast growth factor expression in photoreceptors in vivo and ameliorate light damage. J Neurosci. 1996;16(19):5986-5992.
24. 2-Adrenoceptoragonists inhibit vitreal glutamate and aspartate accumulation and preserve retinal function after transient ischemia. J Pharmacol Exp Ther. 2001;296(1):216-223.
25. Burke J, Schwartz M. Preclinical evaluation of brimonidine. Surv Ophthalmol. 1996;41(suppl 1):S9-S18.
26. Acheampong AA, Shackleton M, Tang-Liu DD. Comparative ocular pharmaco- kinetics of brimonidine after a single dose application to the eyes of albino and pigmented rabbits. Drug Metab Dispos. 1995;23(7):708-712.
27. Wheeler LA, Lai R, Woldemussie E. From the lab to the clinic: activation of an alpha-2 agonist pathway is neuroprotective in models of retinal and optic nerve injury. Eur J Ophthalmol. 1999;9(suppl 1):S17-S21.
28. 2-selective adrenergic agonists against ischemia-induced retinal ganglion cell death. Invest Ophthalmol Vis Sci. 2001;42(9):2074-2084.
29. Vidal-Sanz M, Lafuente M, Mayor S, Miralles de Imperial J, Villegas- Perez MP. Retinal ganglion cell death induced by retinal ischemia: neuroprotective effects of two alpha-2 agonists. Surv Ophthalmol. 2001;45(suppl 3):S261-S267.
30. Danylkova NO, Alcala SR, Pomeranz HD, McLoon LK. Neuroprotective effects of brimonidine treatment in a rodent model of ischemic optic neuropathy. Exp Eye Res. 2007;84(2):293-301.
31. Levkovitch- Verbin H, Harris-Cerruti C, GronerY, Wheeler LA, Schwartz M, Yoles E. RGC death in mice after optic nerve crush injury: oxidative stress and neuroprotection. Invest Ophthalmol Vis Sci. 2000;41(13):4169-4174.
32. Selles- Navarro I, Villegas- Perez MP, Salvador M, Ruiz-Gomez JM, Vidal- Sanz M. Retinal ganglion cell death after different transient periods of pressure- induced ischemia and survival intervals: a quantitative in vivo study. Invest Ophthalmol Vis Sci. 1996;37(10):2002-2024.
33. Wheeler LA, Woldemussie E. Alpha-2 adrenergic receptor agonists are neuro- protective in experimental models of glaucoma. Eur J Ophthalmol. 2001;11 (suppl 2):S30-S35.
34. WoldeMussie E, Ruiz G, Wijono M, Wheeler LA. Neuroprotection of retinal ganglion cells by brimonidine in rats with laser-induced chronic ocular hypertension. Invest Ophthalmol Vis Sci. 2001;42(12):2849-2855.
35. Lafuente MP, Villegas- Pérez MP, Mayor S, Aguilera E, Miralles de Imperial J, Vidal-Sanz M. Neuroprotective effects of brimonidine against transient ischemia- induced retinal ganglion cell death: a dose response in vivo study. Exp Eye Res. 2002;74(2):181-189.
36. Mayor- Torroglosa S, De la Villa P, Rodriguez ME, et al. Ischemia results 3 months later in altered ERG, degeneration of inner layers, and deafferented tectum: neuroprotection with brimonidine. Invest Ophthalmol Vis Sci. 2005;46(10):3825-3835.
37. MacCumber MW, D'Anna SA. Endothelin receptor-binding subtypes in the human retina and choroid. Arch Ophthalmol. 1994;112(9):1231-1235.
38. Yoles E, Schwartz M. Elevations of intraocular glutamate levels in rats with partial lesion of the optic nerve. Arch Ophthalmol. 1998;116(7):906-910.
39. Gao H, Qiao X, Cantor LB, WuDunn D. Upregulation of brain-derived neuro- trophic factor expression by brimonidine in rat retinal ganglion cells. Arch Ophthalmol. 2002;120(6):797-803.
40. Lai RK, Chun T, Hasson D, Lee S, Mehrbod F, Wheeler LA. Alpha-2 adrenocep- tor agonist protects retinal function after acute retinal ischemic injury in the rat. Vis Neurosci. 2002;19(2):175-185.
41. Lönngren U, Näpänkangas U, Lafuente M, et al. The growth factor response in ischemic rat retina and superior colliculus after brimonidine treatment. Brain Res Bull. 2006;71(1-3):208-218.
42. Logan A, Ahmed Z, Baird A, Gonzalez AM, Berry M. Neurotrophic factor synergy is required for neuronal survival and disinhibited axon regeneration after CNS injury. Brain. 2006;129(pt 2):490-502.
43. Fazzone HE, Kupersmith MJ, Leibmann J. Does topical brimonidine tartrate help NAION? Br J Ophthalmol. 2003;87(9):1193-1194.
44. Wilhelm B, Lüdtke H, Wilhelm H; BRAION Study Group. Efficacy and tolerability of 0.2% brimonidine tartrate for the treatment of acute non- arteritic anterior ischemic optic neuropathy (NAION): a 3-month, double-masked, randomised, placebo-controlled trial. Graefes Arch Clin Exp Ophthalmol. 2006;244(5):551- 558.
45. Newman NJ, Biousse V, David R, et al. Prophylaxis for second eye involvement in Leber's hereditary optic neuropathy: an open-labeled, non-randomized mul- ticentertrial of topical brimonidine purite. Am J Ophthalmol. 2005;140(3):407-411.
46. Merin S, Odbolensky A, Farber M, Chowers I. A pilot study of topical treatment with an alpha2-agonist in patients with retinal dystrophies. J Ocul Pharmacol Ther. 2008;24(1):80-86.
47. Ferencz JR, Gilady G, Harel O, Belkin M, Assia EI. Topical brimonidine reduces collateral damage caused by laser photocoagulation for choroidal neovascularization. Graefes Arch Clin Exp Ophthalmol. 2005;243(9):877-880.
48. Onda E, Cioffi GA, Bacon DR, Van Buskirk EM. Microvasculature of the human optic nerve. Am J Ophthalmol. 1995;120(1):92-102.